- Fortress Biotech ( NASDAQ: FBIO ) appoints David Jin as CFO succeeding Robyn Hunter, effective August 16, 2022 and will also continue to serve as Head of Corporate Development.
- Ms. Hunter will step down from the company after 11 years with the company to pursue external opportunities.
- Mr. Jin has been a core member of the Fortress team since joining in 2020 and also serves as Interim Chief Executive Officer and Chief Financial Officer of Avenue Therapeutics ( ATXI ), a Fortress partner company.
For further details see:
David Jin is the new finance chief of Fortress Biotech